{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:47:03Z","timestamp":1787939223726,"version":"build-2784847793"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transsphenoidal adenomectomy (TSS) of somatotroph pituitary neuroendocrine tumor (PitNET) is the first-line treatment of acromegaly. Pharmacological treatment is recommended if surgery is contraindicated or did not lead to disease remission. The choice of treatment best fitting each patient should be based on thorough investigation of patients\u2019 characteristics. The current analysis attempts to create a tool for personalized treatment planning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to assess whether clinical, biochemical, imaging and pathological characteristics can predict surgical remission and response to first-generation somatostatin receptor ligands (SRLs) and pasireotide-LAR in acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A retrospective study of 153 acromegaly patients, treated in the Department of Endocrinology in Bielanski Hospital in Warsaw, Poland was performed. Data on demographics, hormonal and imaging results, pathological evaluation, and treatment outcome was extracted from the Polish Acromegaly Registry collecting information from 11 endocrinology centers in Poland and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with surgical remission had lower GH and IGF-1 concentrations at diagnosis (median GH 5.5 \u00b5g\/L [IQR: 3.1-16.0]\n                      <jats:italic>vs<\/jats:italic>\n                      . 19.9 \u00b5g\/L [IQR: 9.8-42.4], p=&amp;lt;0.001 and mean IGF-1 3.1xULN \u00b1 SD=1.2 vs. 3.7xULN \u00b1 SD=1.2, p=0.007, respectively) and smaller tumors (median 12.5mm [IQR: 9-19] vs. 23mm [IQR: 18-30], p&amp;lt;0.001). These tumors were more often densely granulated (DG) (73.2% vs. 40.0%, p=0.001) with positive staining for alpha-subunit (\u03b1-SU) (58.3% vs. 35.5%, p=0.021) and lower Ki-67 index (p=0.002). Patients responding well to SRLs were more often male (55.6% vs 44.4%, p=0.026), presented lower GH concentration (median GH 17.2 \u00b5g\/L [IQR: 6.2-29.0] vs. 23.8 \u00b5g\/L [IQR: 11.2-49.5], p=0.048) and had more often DG tumors (63.0% vs. 14.3%, p&amp;lt;0.001). No significant differences between good and poor-response to pasireotide-LAR groups were found. In multivariate logistic regression analysis fasting GH concentration &amp;lt;8.63 \u00b5g\/L, maximal tumor diameter &amp;lt;15.5mm, normoprolactinemia and DG tumor turned out to be independent predictors of surgical remission (OR=0.92, p=0.026; OR=0.87, p=0.069, OR=3.86, p=0.096 and OR=3.05, p=0.181, respectively). Fasting GH concentration &amp;lt;36.6 \u00b5g\/L and DG tumor turned out to be independent predictors of good response to first-generation SRLs (OR=0.96, p=0.06 and OR=10.68, p=0.002, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Younger age at diagnosis, male sex, lower GH, IGF-1 and PRL concentrations, smaller tumor size at diagnosis as well as positive \u03b1-SU staining, lower Ki-67 index and DG tumors predicted better treatment outcome in acromegaly patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.957301","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T06:12:42Z","timestamp":1663308762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly"],"prefix":"10.3389","volume":"13","author":[{"given":"Agnieszka","family":"Tomasik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stelmachowska-Bana\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maksymowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Czajka-Oraniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Raczkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Zieli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kunicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Zgliczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"L5","DOI":"10.1530\/EJE-19-0509","article-title":"Mortality in acromegaly decreased in the last decade: A systematic review and meta-analysis","volume":"181","author":"Bolfi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: An update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4158\/EP14430.RA","article-title":"Acromegaly: Assessing the disorder and navigating therapeutic options for treatment","author":"Melmed","year":"2014","journal-title":"Endocr Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: A structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100611","article-title":"Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature","volume":"10","author":"Minniti","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3171\/2013.8.JNS13224","article-title":"Treatment of acromegaly by endoscopic transsphenoidal surgery: Surgical experience in 214 cases and cure rates according to current consensus criteria","volume":"119","author":"Hazer","year":"2013","journal-title":"J Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: Remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1036","article-title":"Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission","volume":"98","author":"Starke","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01844","article-title":"Age- and sex-specific differences as predictors of surgical remission among patients with acromegaly","volume":"103","author":"Park","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0033-1354578","article-title":"Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly","volume":"75","author":"Sun","year":"2014","journal-title":"J Neurol Surg B Skull Base"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.05.058","article-title":"T2-weighted magnetic resonance imaging as a novel predictor of surgical remission in newly diagnosed pituitary macroadenomas presenting as acromegaly","volume":"90","author":"Akkaya","year":"2021","journal-title":"J Clin Neurosci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1989.tb00264.x","article-title":"Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release","volume":"30","author":"Hofland","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-4-859","article-title":"Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: Clinically nonfunctioning and somatotroph adenomas","volume":"70","author":"Oppenheim","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0528","article-title":"Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies","volume":"26","author":"Qiao","year":"2020","journal-title":"Endocr Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1055\/a-1247-4713","article-title":"Multicenter, observational study of lanreotide autogel for the treatment of patients with acromegaly in routine clinical practice in Germany, Austria and Switzerland","volume":"129","author":"St\u00f6rmann","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: A real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: A large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30186-X","article-title":"Shrinkage of pituitary adenomas with pasireotide - authors' reply","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-Head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01824","article-title":"Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs","volume":"152","author":"Petrossians","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03139.x","article-title":"Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide","volume":"68","author":"Karavitaki","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5603\/EP.a2018.0093","article-title":"Diagnostics and treatment of acromegaly - updated recommendations of the polish society of endocrinology","volume":"70","author":"Bolanowski","year":"2019","journal-title":"Endokrynol Pol"},{"key":"B32","first-page":"59","article-title":"Consensus statement of the polish society for endocrinology: Presurgical somatostatin analogs therapy in acromegaly","volume":"29","author":"Bolanowski","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2020.0011","article-title":"Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre","volume":"71","author":"Rak","year":"2020","journal-title":"Endokrynol Pol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.55418\/9781933477152","volume-title":"AFIP atlas of tumor pathology, tumors of the pituitary gland","author":"Asa","year":"2011"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01296-4","article-title":"Predictive model of surgical remission in acromegaly: Age, presurgical GH levels and knosp grade as the best predictors of surgical remission","volume":"44","author":"Araujo-Castro","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03669-4","article-title":"Predictors of postoperative biochemical remission in acromegaly","volume":"151","author":"Yao","year":"2021","journal-title":"J Neurooncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02123-4","article-title":"Gender differences and temporal trends over two decades in acromegaly: A single center study in 112 patients","volume":"67","author":"Ioachimescu","year":"2020","journal-title":"Endocrine"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.12.7042","article-title":"Ten-year follow-up results of transsphenoidal microsurgery in acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021822","article-title":"Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission","volume":"88","author":"De","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.09.004","article-title":"Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly","volume":"126","author":"Sarkar","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.4.7398","article-title":"Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-23197","article-title":"A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: Prognostic value of preoperative plasma prolactin","volume":"34","author":"De Marinis","year":"2002","journal-title":"Horm Metab Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/EJE-11-1119","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: Clinical analysis of 279 cases","volume":"166","author":"Wang","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: Imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-014-2230-6","article-title":"An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly","volume":"156","author":"Sarkar","year":"2014","journal-title":"Acta Neurochir (Wien)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3171\/2018.4.JNS18230","article-title":"Growth hormone and prolactin-staining tumors causing acromegaly: A retrospective review of clinical presentations and surgical outcomes","volume":"131","author":"Rick","year":"2018","journal-title":"J Neurosurg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347322","article-title":"Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas","volume":"21","author":"Vantyghem","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-004-9010-y","article-title":"The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours","volume":"26","author":"Wa\u015bko","year":"2004","journal-title":"Pharm World Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4103\/1793-5482.142732","article-title":"The impact of immunohistochemical markers of ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study","volume":"9","author":"Alimohamadi","year":"2014","journal-title":"Asian J Neurosurg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.81983","article-title":"Associations of ki-67 labeling index with clinical and paraclinical features of growth hormone-secreting pituitary adenomas: A single center report from Iran","volume":"17","author":"Mohseni","year":"2019","journal-title":"Int J Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2018.0001","article-title":"Markers of proliferation and invasiveness in somatotropinomas","volume":"69","author":"Baldys-Waligorska","year":"2018","journal-title":"Endokrynol Pol"},{"key":"B61","article-title":"Role of ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese patients","volume":"28","author":"Huan","year":"2015","journal-title":"Pak J Pharm Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199307000-00003","article-title":"Growth hormone-producing pituitary adenomas: Correlations between clinical characteristics and morphology","volume":"33","author":"Yamada","year":"1993","journal-title":"Neurosurgery"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12902-021-00850-2","article-title":"Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: A retrospective cohort study","volume":"21","author":"Dehghani","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 world health organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.957301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T04:34:28Z","timestamp":1676781268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.957301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":67,"alternative-id":["10.3389\/fendo.2022.957301"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.957301","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"957301"}}